Biomarkers for Response to Neoadjuvant Chemoradiation for Rectal Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 3, 2009, Pages 673-688

  Kuremsky, Jeffrey G ^a,b   Tepper, Joel E ^b   McLeod, Howard L ^a,b  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Biomarkers; Chemoradiation; Neoadjuvant; Predictive; Rectal cancer

Indexed keywords

CHEMORADIATION; CLINICAL TRIAL; EPIDERMAL GROWTH FACTOR RECEPTORS; GERMLINE; INITIAL ASSESSMENT; LITERATURE SEARCH; MOLECULAR BIOMARKER; NEOADJUVANT; NEOADJUVANT CHEMORADIATION; NEOADJUVANT THERAPY; PRE-TREATMENT; PREDICTING OUTCOMES; PREDICTIVE; RECTAL CANCER; THYMIDYLATE SYNTHASE;

BIOACTIVITY; CHEMOTHERAPY; DNA; ENZYMES; GENES; NUCLEIC ACIDS; PARAMAGNETIC RESONANCE; PEPTIDES; POLYMORPHISM;

BIOMARKERS;

CARBOPLATIN; CELECOXIB; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KI 67 ANTIGEN; OXALIPLATIN; PANITUMUMAB; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TEGAFUR; THYMIDYLATE SYNTHASE; TUMOR MARKER; UFT;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CANCER; GENE EXPRESSION; GENE MUTATION; HUMAN; METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; TUMOR BIOPSY;

BCL-2-ASSOCIATED X PROTEIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; KI-67 ANTIGEN; MICROARRAY ANALYSIS; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 67049171133     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.03.003     Document Type: Review

References (76)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2008 58 (2008) 71-96
2. Gunderson L.L., Sargent D.J., Tepper J.E., et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: A pooled analysis. Int J Radiat Oncol Biol Phys 54 (2002) 386-396
3. Mohiuddin M., Marks J., and Marks G. Management of rectal cancer: Short- vs. long-course preoperative radiation. Int J Radiat Oncol Biol Phys 72 (2008) 636-643
4. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
5. Nelson H., and Sargent D.J. Refining multimodal therapy for rectal cancer. N Engl J Med 345 (2001) 690-692
6. Kapiteijn E., Marijnen C.A., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345 (2001) 638-646
7. Janjan N.A., Khoo V.S., Abbruzzese J., et al. Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 44 (1999) 1027-1038
8. Kim J.S., Kim J.S., Cho M.J., et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 54 (2002) 403-408
9. Glynne-Jones R., and Harrison M. Locally advanced rectal cancer: What is the evidence for induction chemoradiation?. Oncologist 12 (2007) 1309-1318
10. Crane C.H., Skibber J.M., Feig B.W., et al. Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma. Cancer 97 (2003) 517-524
11. Rodel C., Martus P., Papadoupolos T., et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23 (2005) 8688-8696
12. Valentini V., Coco C., Picciocchi A., et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. Int J Radiat Oncol Biol Phys 53 (2002) 664-674
13. Kuerbitz S.J., Plunkett B.S., Walsh W.V., et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 89 (1992) 7491-7495
14. Lowe S.W., Ruley H.E., Jacks T., et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
15. Lowe S.W., Schmitt E.M., Smith S.W., et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362 (1993) 847-849
16. McIlwrath A.J., Vasey P.A., Ross G.M., et al. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 54 (1994) 3718-3722
17. Rau B., Sturm I., Lage H., et al. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol 21 (2003) 3391-3401
18. Bertolini F., Bengala C., Losi L., et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1455-1461
19. Saw R.P., Morgan M., Koorey D., et al. p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 46 (2003) 192-202
20. Chang H.J., Jung K.H., Kim D.Y., et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum Pathol 36 (2005) 364-371
21. Terzi C., Canda A.E., Sagol O., et al. Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 23 (2008) 37-45
22. Rodel F., Hoffmann J., Grabenbauer G.G., et al. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178 (2002) 426-435
23. Scott N., Hale A., Deakin M., et al. A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: Relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol 24 (1998) 169-173
24. Tannapfel A., Nusslein S., Fietkau R., et al. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 41 (1998) 585-591
25. Diez M., Ramos P., Medrano M.J., et al. Preoperatively irradiated rectal carcinoma: Analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology 64 (2003) 213-219
26. Kim N.K., Park J.K., Lee K.Y., et al. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 8 (2001) 418-424
27. Elsaleh H., Robbins P., Joseph D., et al. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?. Radiother Oncol 56 (2000) 239-244
28. Charara M., Edmonston T.B., Burkholder S., et al. Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 24 (2004) 3161-3167
29. Okonkwo A., Musunuri S., Talamonti M., et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep 8 (2001) 497-500
30. Reerink O., Karrenbeld A., Plukker J.T., et al. Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy. Anticancer Res 24 (2004) 1217-1221
31. Kudrimoti M., Lee E.Y., Kang Y., et al. Genetic markers predictive of response to induction chemoradiotherapy for locally advanced rectal cancers. J Ky Med Assoc 105 (2007) 18-22
32. Jakob C., Liersch T., Meyer W., et al. Predictive value of Ki67 and p53 in locally advanced rectal cancer: Correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 14 (2008) 1060-1066
33. Negri F.V., Campanini N., Camisa R., et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 98 (2008) 143-147
34. Lin L.C., Lee H.H., Hwang W.S., et al. p53 and p27 as predictors of clinical outcome for rectal-cancer patients receiving neoadjuvant therapy. Surg Oncol 15 (2006) 211-216
35. Luna-Perez P., Arriola E.L., Cuadra Y., et al. p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 5 (1998) 203-208
36. Spitz F.R., Giacco G.G., Hess K., et al. p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 3 (1997) 1685-1690
37. Esposito G., Pucciarelli S., Alaggio R., et al. P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 8 (2001) 311-318
38. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5 (1999) 2884-2890
39. Liang K., Ang K.K., Milas L., et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57 (2003) 246-254
40. Goldstein N.S., and Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system. Cancer 92 (2001) 1331-1346
41. Giralt J., de las Heras M., Cerezo L., et al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: A multicenter, retrospective analysis. Radiother Oncol 74 (2005) 101-108
42. Kim J.S., Kim J.M., Li S., et al. Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 66 (2006) 195-200
43. Spindler K.L., Nielsen J.N., Lindebjerg J., et al. Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 66 (2006) 500-504
44. Spindler K.L., Nielsen J.N., Lindebjerg J., et al. Germline polymorphisms may act as predictors of response to preoperative chemoradiation in locally advanced T3 rectal tumors. Dis Colon Rectum 50 (2007) 1363-1369
45. Salonga D., Danenberg K.D., Johnson M., et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6 (2000) 1322-1327
46. Lenz H.J., Danenberg K.D., Leichman C.G., et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 4 (1998) 1227-1234
47. Pullarkat S.T., Stoehlmacher J., Ghaderi V., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1 (2001) 65-70
48. Mandola M.V., Stoehlmacher J., Zhang W., et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14 (2004) 319-327
49. Mandola M.V., Stoehlmacher J., Muller-Weeks S., et al. A novel single nucleotide polymorphism within the 5' tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63 (2003) 2898-2904
50. Marcuello E., Altes A., del Rio E., et al. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients. Int J Cancer 112 (2004) 733-737
51. Villafranca E., Okruzhnov Y., Dominguez M.A., et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19 (2001) 1779-1786
52. Horie N., Aiba H., Oguro K., et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20 (1995) 191-197
53. Kawakami K., Salonga D., Park J.M., et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7 (2001) 4096-4101
54. Scholzen T., and Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 182 (2000) 311-322
55. Brown D.C., and Gatter K.C. Ki67 protein: The immaculate deception?. Histopathology 40 (2002) 2-11
56. Rodel C., Grabenbauer G.G., Papadopoulos T., et al. Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52 (2002) 294-303
57. el-Deiry W.S., Harper J.W., O'Connor P.M., et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54 (1994) 1169-1174
58. Lu Y., Yamagishi N., Yagi T., et al. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. Oncogene 16 (1998) 705-712
59. Waldman T., Lengauer C., Kinzler K.W., et al. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381 (1996) 713-716
60. Wouters B.G., Giaccia A.J., Denko N.C., et al. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 57 (1997) 4703-4706
61. Wang Y.A., Elson A., and Leder P. Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci U S A 94 (1997) 14590-14595
62. Tian H., Wittmack E.K., and Jorgensen T.J. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res 60 (2000) 679-684
63. Yamaguchi H., Bhalla K., and Wang H.G. Bax plays a pivotal role in thapsigargin-induced apoptosis of human colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2 release from mitochondria. Cancer Res 63 (2003) 1483-1489
64. Wagener C., Bargou R.C., Daniel P.T., et al. Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer 67 (1996) 138-141
65. Zhang L., Yu J., Park B.H., et al. Role of BAX in the apoptotic response to anticancer agents. Science 290 (2000) 989-992
66. Walton M.I., Whysong D., O'Connor P.M., et al. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res 53 (1993) 1853-1861
67. Miyashita T., and Reed J.C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52 (1992) 5407-5411
68. Fukunaga-Johnson N., Ryan J.J., Wicha M., et al. Bcl-2 protects murine erythroleukemia cells from p53-dependent and -independent radiation-induced cell death. Carcinogenesis 16 (1995) 1761-1767
69. Ghadimi B.M., Grade M., Difilippantonio M.J., et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23 (2005) 1826-1838
70. Rimkus C., Friederichs J., Boulesteix A.L., et al. Microarray-based prediction of tumor response to neoadjuvant radiochemotherapy of patients with locally advanced rectal cancer. Clin Gastroenterol Hepatol 6 (2008) 53-61
71. Read T.E., McNevin M.S., Gross E.K., et al. Neoadjuvant therapy for adenocarcinoma of the rectum: Tumor response and acute toxicity. Dis Colon Rectum 44 (2001) 513-522
72. Stoehlmacher J., Goekkurt E., Mogck U., et al. Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. Cancer Lett 272 (2008) 221-225
73. Terrazzino S., Agostini M., Pucciarelli S., et al. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. Pharmacogenet Genomics 16 (2006) 817-824
74. Debucquoy A., Goethals L., Geboes K., et al. Molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol 80 (2006) 172-177
75. Smith F.M., Reynolds J.V., Kay E.W., et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 466-472
76. Debucquoy A., Libbrecht L., Roobrouck V., et al. Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: Prognostic value and effects of preoperative radio (chemo) therapy. Eur J Cancer 44 (2008) 791-797